Uncontrolled trial strategy sinks UroGen
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
Asia stymies Columvi's expansion
Starglo isn't applicable to a US population, an adcom rules.
J&J gets a smouldering endorsement
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
AbbVie gets a cMet niche
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
